Showing 21-30 of 2027 results for "".
ISDPA: Dr. Bhatia and Dr. Zirwas Discuss the Itchy Patient
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-bhatia-and-dr-zirwas-discuss-itchy-patient/27065/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, talks with Matthew Zirwas, MD, about Dr. Zirwas’s lecture on the itchy patient and the latest solutions for itch at the Illinois Society of Dermatology Physician Assistants (ISDPA) Midwest Dermatology Conference 2024.Tolerability of JAK Inhibitors Used in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/tolerability-of-jak-inhibitors-used-in-dermatology/20126/Although safety and tolerability are often intertwined, they are distinct considerations. Topical and oral JAKs used in dermatology today seem to offer good tolerability. Adelaide A. Hebert, MD and Matthew Zirwas, MD discuss potential side effects, management, and monitoring in pediatric and adult pEczematous Dermatitis: Dr. Zirwas
https://practicaldermatology.com/programs/practical-dermatology/eczematous-dermatitis-dr-zirwas/32689/Matthew Zirwas, MD, talks about the therapeutic strategies for non-atopic dermatitis—particularly hand dermatitis and facial dermatitis—that he covered during "Eczematous Dermatitis Update 2025: Contact, Hand, Head and Neck, Eyelid and More" at Maui Derm 2025.Updates from CSF 2017
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-updates-from-csf-2017/18371/Dermatologists and core cosmetic physicians shared new insights and reviewed the developments in clinical and cosmetic dermatology at the ninth annual Cosmetic Surgery Forum in Las Vegas. Matthew Zirwas, MD addressed interest in oral supplements to support skin health. Neurotoxin pioneer Nick Lowe,Analyzing Safety Data From Level Up
https://practicaldermatology.com/series/the-practical-dermatology-podcast/analyzing-safety-data-from-level-up/33944/The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib. Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versuJournal Club: Dupilumab and Risk of Malignancy
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national databaseIntergenerational Dermatology: Two Generations of Dermatologists Reflect on the Field
https://practicaldermatology.com/topics/general-topics/intergenerational-dermatology-two-generations-of-dermatologists-reflect-on-the-field-2/23937/With Heidi A. Waldorf, MD, and Donald S. Waldorf, MDStaphylococcus aureus Colonization
https://practicaldermatology.com/issues/september-2025/staphylococcus-aureus-colonization/37626/In a recent review article, Piewngam and Otto examined the epidemiology, mechanisms, and clinical implications of Staphylococcus aureus (S. aureus) colonization, while evaluating both current and emerging strategies for decolonization.Intergenerational Dermatology: Three Generations of Dermatologists Reflect on the Field
https://practicaldermatology.com/topics/general-topics/intergenerational-dermatology-three-generations-of-dermatologists-reflect-on-the-field/23992/With Sorrel S. Resnik, MD, Barry Resnik, MD, and Sydney Resnik, MD, by Heidi SpleteWhat's New In Retirement Planning?
https://practicaldermatology.com/topics/practice-management/whats-new-in-retirement-planning/21249/Defined benefit plans can provide larger tax deductions than 401(k)s/profit-sharing plans.